This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
4 - 6 June, 2024
Excel London Platinum Suite

Matthias Peipp, PhD
Professor and Head of Research at Christian-Albrechts-University Kiel
Speaker

Profile

Matthias Peipp received his PhD at the chair of genetics, Friedrich-Alexander-University, Erlangen-Nuremberg, Germany in 2003. In 2004, he moved to the Christian-Albrechts-University of Kiel (Kiel, Germany), where he studied effector mechanisms mediated by human EGFR antibodies. In 2006, Matthias moved to the Division of Stem Cell Transplantation and Immunotherapy (Kiel, Germany) where he is heading the research division and a research group interested in antibody-based immunotherapy of cancer. In 2015 Matthias was awarded an endowed professorship “Mildred-Scheel-Professorship for experimental antibody-based cancer immunotherapy” funded by the German Cancer Aid. His current work is focused on antibody engineering to improve cancer immunotherapy.

Agenda Sessions

  • Activating NK Cell Receptors as Trigger Molecules for Bispecific Antibodies or Fc-Engineered Antibodies to Enhance Anti-Tumor NK Cell Responses

    14:35